ATE252885T1 - Plan zur verabreichung von h+, k+-atpase inhibitoren - Google Patents

Plan zur verabreichung von h+, k+-atpase inhibitoren

Info

Publication number
ATE252885T1
ATE252885T1 AT97930933T AT97930933T ATE252885T1 AT E252885 T1 ATE252885 T1 AT E252885T1 AT 97930933 T AT97930933 T AT 97930933T AT 97930933 T AT97930933 T AT 97930933T AT E252885 T1 ATE252885 T1 AT E252885T1
Authority
AT
Austria
Prior art keywords
administration
plan
atpase
atpase inhibitors
extended
Prior art date
Application number
AT97930933T
Other languages
English (en)
Inventor
Christer Cederberg
George Sachs
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE252885T1 publication Critical patent/ATE252885T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97930933T 1996-06-20 1997-06-18 Plan zur verabreichung von h+, k+-atpase inhibitoren ATE252885T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals
PCT/SE1997/001098 WO1997048380A1 (en) 1996-06-20 1997-06-18 ADMINISTRATION REGIMEN OF H+, K+-ATPase INHIBITORS

Publications (1)

Publication Number Publication Date
ATE252885T1 true ATE252885T1 (de) 2003-11-15

Family

ID=20403092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930933T ATE252885T1 (de) 1996-06-20 1997-06-18 Plan zur verabreichung von h+, k+-atpase inhibitoren

Country Status (28)

Country Link
US (4) US20010008900A1 (de)
EP (1) EP0921787B1 (de)
JP (1) JP2000512993A (de)
CN (1) CN1178648C (de)
AT (1) ATE252885T1 (de)
AU (1) AU726859B2 (de)
BR (1) BR9709838A (de)
CA (1) CA2257405A1 (de)
CZ (1) CZ298213B6 (de)
DE (1) DE69725860T2 (de)
DK (1) DK0921787T3 (de)
EE (1) EE04606B1 (de)
ES (1) ES2208921T3 (de)
HK (1) HK1018590A1 (de)
HU (1) HUP9901794A3 (de)
IL (2) IL127542A0 (de)
IS (1) IS2216B (de)
NO (1) NO323295B1 (de)
NZ (1) NZ332990A (de)
PL (1) PL189716B1 (de)
PT (1) PT921787E (de)
RS (1) RS49590B (de)
RU (1) RU2203662C2 (de)
SE (1) SE9602442D0 (de)
SK (1) SK284204B6 (de)
TR (1) TR199802647T2 (de)
UA (1) UA64715C2 (de)
WO (1) WO1997048380A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AU3870599A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. R-rabeprazole compositions and methods
EP1073333A4 (de) * 1998-04-30 2005-06-15 Sepracor Inc S-rabeprazol enthaltende zusammensetzungen und verfahren
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
PT1105105E (pt) 1998-08-12 2006-07-31 Altana Pharma Ag Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DE69522921T2 (de) * 1994-07-08 2002-04-11 Astrazeneca Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
YU56698A (sh) 2004-12-31
SE9602442D0 (sv) 1996-06-20
CZ298213B6 (cs) 2007-07-25
SK165598A3 (en) 1999-08-06
IS4923A (is) 1998-12-15
DE69725860T2 (de) 2004-09-09
RU2203662C2 (ru) 2003-05-10
NZ332990A (en) 2000-07-28
IL127542A (en) 2006-08-01
US20070276007A1 (en) 2007-11-29
ES2208921T3 (es) 2004-06-16
TR199802647T2 (xx) 1999-03-22
UA64715C2 (en) 2004-03-15
EP0921787A1 (de) 1999-06-16
IL127542A0 (en) 1999-10-28
HUP9901794A3 (en) 2002-11-28
HUP9901794A2 (hu) 2000-04-28
NO985964L (no) 1999-02-22
NO323295B1 (no) 2007-03-05
SK284204B6 (sk) 2004-10-05
DK0921787T3 (da) 2004-02-23
WO1997048380A1 (en) 1997-12-24
US20050113418A1 (en) 2005-05-26
US20010008900A1 (en) 2001-07-19
EE9800435A (et) 1999-06-15
AU726859B2 (en) 2000-11-23
RS49590B (sr) 2007-06-04
IS2216B (is) 2007-03-15
PT921787E (pt) 2004-03-31
CZ420398A3 (cs) 2000-02-16
PL189716B1 (pl) 2005-09-30
NO985964D0 (no) 1998-12-18
PL330910A1 (en) 1999-06-07
EE04606B1 (et) 2006-04-17
DE69725860D1 (de) 2003-12-04
JP2000512993A (ja) 2000-10-03
CN1178648C (zh) 2004-12-08
CN1222074A (zh) 1999-07-07
AU3469097A (en) 1998-01-07
CA2257405A1 (en) 1997-12-24
EP0921787B1 (de) 2003-10-29
HK1018590A1 (en) 1999-12-30
US20090036494A1 (en) 2009-02-05
BR9709838A (pt) 1999-08-10

Similar Documents

Publication Publication Date Title
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
SE9704870D0 (sv) New pharmaceutical formulation I
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
SE9504661D0 (sv) New compounds
AU2001231763A1 (en) Dosing regimen
DK0650483T3 (da) (3R,4R)-Delta6-tetrahydrocannabinol-7-syrer
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
AP9701041A0 (en) Pyridylpyrrole compounds.
DE69033970D1 (de) Huperzin a analoge verbindungen
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
SE9504662D0 (sv) New compounds
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
DK0783319T3 (da) Muramylpeptid-sammensætninger til inhibering af HIV replikation
HK1045253B (zh) 治療或預防動脈硬化和狹窄的苯乙酸組合物
RS53223B (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0921787

Country of ref document: EP

REN Ceased due to non-payment of the annual fee